Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women

Current Medical Research and Opinion

Volumn 30, Issue 8, 2014, Pages 1617-1626

  Ellis, Alexandra G ^a   Reginster, Jean Yves ^b   Luo, Xuemei ^c   G Bushmakin, Andrew ^c   Williams, Robert ^c   Sutradhar, Santosh ^c   Mirkin, Sebastian ^c   Jansen, Jeroen P ^a,d  

^a Mapi Group   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c PFIZER INC   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bazedoxifene; Bisphosphonates; Fractures; Indirect comparison; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; INDOLE DERIVATIVE;

ARTICLE; DRUG EFFICACY; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; META ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SPINE FRACTURE; SYSTEMATIC REVIEW; COMPARATIVE STUDY; COMPLICATION; FEMALE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; REGRESSION ANALYSIS; SPINAL FRACTURES; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; INDOLES; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 84904878917     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.908279     Document Type: Article

References (28)

1. Deal CL. Osteoporosis: prevention, diagnosis, and management. Am J Med 1997;102:35S-39S
2. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-75
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33
4. Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160
5. Stevenson M, Davis S, Lloyd-Jones M, et al. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess 2007;11:1-134
6. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005;16:229-38
7. Crandall CJ, Newberry SJ, Gellad WG, et al. Treatment to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis: Update of a 2007 Report. Comparative Effectiveness Review No. 53. (Prepared by Southern California Evidence-based Practice Center under Contract No. HHSA-290- 2007-10062-I.) Rockville, MD: Agency for Healthcare Research and Quality, March 2012. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm [Last accessed 20 February 2014]
8. EMA European Medicines Agency. Assessment Report for Conbriza. Procedure No. EMEA/H/C/913 London, 19 February 2009. Available at: http://www.emea.europa. eu/ema/index.jsp?curl=pages/medicines/human/medicines/000913/humanmed000723.jsp [Last accessed 18 February 2013].
9. Kawate H, Takayanagi R. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clin Interv Aging 2011;6:151-6
10. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
11. Kanis JA, Johansson H, Oden A, et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009;44:1049-54
12. World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAX: WHO Fracture Risk Assessment Tool. Available at: http://www.shef. ac.uk/FRAX/[Last accessed 19 October 2011]
13. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900
14. Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect- treatmentcomparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011;14:429-37
15. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28
16. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24
17. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001;10:277-303
18. Cooper H, Patall EA. The relative benefits of meta-analysis conducted with individual participant data versus aggregated data. Psychol Methods 2009;14:165-76
19. Spiegelhalter D, Thomas A, Best N, et al. WinBUGS User Manual: Version 1.4. Cambridge: MRC Biostatistics Unit, 2003
20. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
21. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
22. Liberman UA, Weiss SR, Brö ll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43
23. Chesnut III CH, Skag A, Christiansen C, et al.; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
24. Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005;21:391-401
25. Delmas PD, Recker RR, Chesnut III CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteo Intl 2004;15:792-8
26. Fogelman I, Ribot C, Smith R, et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 2000;85:1895-900
27. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
28. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91